Detection and Characterization of Pulmonary Disease by Transthoracic Doppler (TTD)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01618721
(Low recruiting rate and fulfill requirements)
The study seeks to characterize data obtained from patients with a variety of lung diseases using ultrasound Doppler signals obtained from lung tissue. A standard ultrasound device in a Doppler mode is placed on the chest wall and the unique software the investigators have developed analyzes the signals reflected from within the lung. On the basis of of pilot studies performed previously the investigators expect to receive different signals from different diseases that will enable diagnosis of different lung diseases.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
All patients are referred to the outpatient pulmonary clinics or PFT lab for further workup
Able and willing to provide informed consent
Age 18 years or older
Clinic and hospital records including additional background medical data such as results of echocardiograms, cardiac catheterization pathology reports etc., available and accessible.
Evaluation by a physician who determines that a High Resolution Computed Tomography (HRCT) of the Thorax and pulmonary function tests, including spirometry, lung volumes and diffusion capacity, are indicated as part of the standard clinical care.
If full lung function tests are normal imaging with a regular chest x-ray is sufficient.
Study Population - subjects will be grouped based on the following criteria after obtaining pulmonary function tests and HRCT of the thorax -
COPD based on clinical assessment and spirometry showing airflow limitation i.e., (FEV1/FVC < 0.70).
Interstitial lung disease (ILD) diagnosed by HRCT.
Control subjects presenting with pulmonary complaints evaluated by full PFTs (spirometry, lung volume and DLCO) and a chest x-ray and/or HRCT , all found to be within normal limits, .
Primary or metastatic lung cancer.
Concomitant or previous diagnosis of Bronchial Asthma.